Staying Diversified, Bayer Sees Opportunities In Digital Innovation
Pharma Has Missed Digital Health Potential
Executive Summary
Despite its Monsanto woes, Bayer is sticking with its diversified portfolio, and is branching out into patient-facing digital health services.
You may also be interested in...
Roundup Lawsuits Overshadow Pharma Growth At Bayer
Pharmaceutical sales hit €4.35bn helped by a strong showing in China but as the number of glyphosate plaintiffs in the US jumps to 42,700, the German group's priority is sorting out Monsanto.
Bayer's Vitrakvi Is EU’s First Tumor-Agnostic Treatment
The German group's cancer drug is the first to be approved for use in Europe for a wide range of tumors. The principal challenge now is to find eligible patients.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.